Bioorganic and medicinal chemistry letters p. 141 - 144 (1999)
Update date:2022-08-03
Topics:
Chu, Guo-Hua
Peters, Amy
Selcer, Kyle W.
Li, Pui-Kai
We report the development of (E)- and (Z)-4-hydroxytamoxifen sulfamates as estrone sulfatase inhibitors, potential therapeutic agents for the treatment of breast cancer. Both compounds competitively inhibit estrone sulfatase isolated from rat liver with apparent Ki of 35.9 μM for (E)-4-hydroxytamoxifen sulfamate and an apparent Ki of >500 μM for the (Z) isomer.
View MoreContact:+86-18653358619
Address:zibo
Shandong Hongxiang Zinc Co., Ltd
Contact:086-0311-66187879
Address:DaWang developing zone
Hebei Fulong Import & Export Co., Ltd.
Contact:86-311-87795661
Address:15A19 Zhongyuan Building,368 Youyi North Street,Shijiazhuang 050070,China
Chongqing Changfeng Chemical Co., Ltd.
website:http://www.changfengchem.com
Contact:+86-23-67896333
Address:30th Floor, Longhu Ziduxingzuo Building A, 1st Branch,YuSong Rd., Yubei District, Chongqing, China
Beijing Cooperate Pharmaceutical Co.,Ltd
website:http://www.cooperate-pharm.com/
Contact:86-01060279497
Address:No.507,Building 4,Tianhua Street, Biomedicine industrial Base
Doi:10.1021/jo9613601
(1997)Doi:10.1021/ja01207a035
(1946)Doi:10.1016/S0040-4039(96)02075-8
(1996)Doi:10.1016/S0960-894X(99)00187-0
(1999)Doi:10.1016/S0968-0896(02)00612-0
(2003)Doi:10.1021/ja963295i
(1997)
